J9350 HCPCS Level II code: Injection, mosunetuzumab-axgb, 1 mg
J9350 is the HCPCS code for “Injection, mosunetuzumab-axgb, 1 mg” in CMS’s October 2026 release, in effect from Oct 1, 2026.
Official description
J9350Injection, mosunetuzumab-axgb, 1 mg
Short description: Inj mosunetuzumab-axgb, 1 mg
HCPCS · United States
Medicare details
The indicators CMS publishes with J9350 in its October 2026 file. They describe Medicare’s handling, not another payer’s.
- Medicare coverage
- Carrier judgment
- Medicare pricing
- Drugs
- ASC
- Approved for ambulatory surgical centers
- Type of service
- Medical care
- BETOS category
- Chemotherapy
- Added
- Jul 1, 2023
Where J9350 sits
- 1J codesDrugs administered other than orally
- 2Active code J9350Injection, mosunetuzumab-axgb, 1 mg
Source and release
- Data release
- HCPCS Level II · October 2026
- Effective date
- Oct 1, 2026
- Publisher
- CMS
This page is built from the HCPCS Level II catalog that Vero Codes reads when it suggests codes: Centers for Medicare & Medicaid Services’s October 2026 release, imported from the publisher’s file and checked against it. The description, notes and structured data come from the same record.
Frequently asked questions
What does HCPCS code J9350 mean?
J9350 is the HCPCS code for “Injection, mosunetuzumab-axgb, 1 mg” in CMS’s HCPCS Level II October 2026 release.
Does Medicare cover J9350?
CMS lists J9350’s Medicare coverage as “Carrier judgment” and its pricing as “Drugs”. Coverage and payment still depend on the patient, the setting, the documentation and the payer.
Which HCPCS Level II release does this page use?
It uses CMS’s October 2026 release, in effect from Oct 1, 2026 to Dec 31, 2026. It is a reference: confirm the code against the current list and the payer’s rules before you submit it.
Codes beside J9350
All J codesJ9341Injection, thiotepa (tepylute), 1 mgJ9342Injection, thiotepa, not otherwise specified, 1 mgJ9345Injection, retifanlimab-dlwr, 1 mgJ9347Injection, tremelimumab-actl, 1 mgJ9348Injection, naxitamab-gqgk, 1 mgJ9349Injection, tafasitamab-cxix, 2 mgJ9351Injection, topotecan, 0.1 mgJ9352Injection, trabectedin, 0.1 mgJ9353Injection, margetuximab-cmkb, 5 mgJ9354Injection, ado-trastuzumab emtansine, 1 mgJ9355Injection, trastuzumab, excludes biosimilar, 10 mgJ9356Injection, trastuzumab, 10 mg and hyaluronidase-oysk